S3014Referred to Committee

Ensuring Timely Access to Generics Act of 2025

Share:
Introduced
In Committee
3
Passed One Chamber
4
Passed Both
5
Signed into Law
119th
Congress
2025-10-16
Introduced
2
Cosponsors
S
ⓘ
Type

Sponsor

Jeanne Shaheen
Jeanne Shaheen
Democrat · NH · Senator
Votes with party: 47.2% (318 recorded votes)

Full profile: /officials/S001181

Source: Congress.gov · FEC

Cosponsors (2)

Members who have signed on to support this bill since introduction. Source: Congress.gov.

Latest Action

The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

2025-10-16

Source: Congress.gov

Committee Activity

Currently in

Previously

Plain-English Summary

The legislation would speed up the process for generic drug manufacturers to bring cheaper alternative versions of brand-name medications to the market, potentially reducing wait times from years to months. By streamlining FDA approval procedures and reducing regulatory barriers, the bill aims to help patients and insurance companies save money on prescription drugs while giving generic manufacturers a faster path to compete. The changes would primarily affect pharmaceutical companies, the FDA, patients who rely on affordable medications, and health insurers.

AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.

Subjects

Health
Full bill text is not yet cached locally.
Open text viewRead on Congress.gov

Related legislation

Bills by the same sponsor or covering overlapping subjects.